Big movers on D-Street: What should investors do with TCS, Natco Pharma and GRSE?

October 11, 2024

Domestic markets closed lower despite the RBI hinting at a rate cut. TCS is showing strong technical resilience and poised for an upward reversal, making it a ‘buy on dips’ candidate. Natco Pharma is in a healthy consolidation phase with potential targets of Rs 1,650–1,720.

More To Explore

BlackBuck gets Buy rating as Ambit sees strong growth ahead, values stock at Rs 885

Ambit Capital initiated coverage on Zinka Logistics, parent of BlackBuck, with a Buy rating and Rs 885 target price. The brokerage highlighted BlackBuck’s emergence as

November 14, 2025

FIIs and DIIs place big bets on State Bank of India — Analysts see about 20% rally ahead

Investors are showing renewed confidence in State Bank of India. Both foreign and domestic institutions are raising their stakes. SBI reported strong earnings momentum. Analysts

November 14, 2025

Advertiser Disclosure

Great-investor.com helps users across the globe to find out The latest news, Guides, and Info about finance and investments. Furthermore, our content and research teams do not participate in any advertising planning nor are they permitted access to advertising campaign data.

Disclaimer

It is our organization’s primary mission to provide reviews, commentary, and analysis that are unbiased and objective. While great-investor.com has some data verified by industry participants, it can vary from time to time. Operating as an online business, this site may be compensated through third party advertisers. Our receipt of such compensation shall not be construed as an endorsement or recommendation by great-investor.com, nor shall it bias our reviews, analysis, and opinions. Please see our General Disclaimers for more information

Top10 International FZ LLE | 17th Floor, Creative Tower | 4422 | Fujairah | TRN: 100608946800003